Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.
Better Therapeutics Inc. (BTTX) is at the forefront of developing prescription digital therapeutics aimed at treating chronic diseases. The company, formerly known as Farewell, leverages a unique combination of software, human coaching enhanced by artificial intelligence, and advanced analytics to address the underlying behaviors causing most chronic conditions. This innovative approach offers scalable solutions capable of impacting millions of lives.
Better Therapeutics' digital therapeutics are grounded in solid evidence and align with existing clinical treatment guidelines. They can be integrated with other interventions or used independently, providing flexible and effective treatment options. The company's non-drug solutions are pivotal in reducing the health and financial burdens of chronic diseases on individuals, healthcare payers, and the broader healthcare system.
Recent achievements include significant advancements in their AI-driven coaching systems and the successful integration of their digital therapeutics into various healthcare settings. Better Therapeutics is continually expanding its partnerships and collaborations to further enhance the reach and effectiveness of its products.
The company's financial health reflects steady growth, driven by its innovative products and expanding market presence. Better Therapeutics remains committed to advancing its mission of improving chronic disease management through cutting-edge digital solutions.
Better Therapeutics, Inc. (NASDAQ: BTTX) has achieved significant research milestones, announcing the first study on nutritional cognitive behavioral therapy (nCBT) for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). This comes after positive primary endpoint data from its BT-001 clinical trial for type 2 diabetes, showing 61% of participants lowered A1c after 90 days. Collaborative studies with Arizona Liver Health, Mass General Brigham, and others aim to evaluate nCBT’s effectiveness in treating cardiometabolic diseases, addressing a growing public health issue.
Better Therapeutics, Inc. (NASDAQ: BTTX), a leader in prescription digital therapeutics, announced that CEO Kevin Appelbaum will participate in a fireside chat at Chardan's Virtual Prescription Digital Therapeutics Summit on April 11, 2022, at 1:30 p.m. ET. This event will focus on the company's innovative approach to nutritional cognitive behavioral therapy aimed at combating cardiometabolic diseases. A live webcast will be available for 90 days on their investor site.
Better Therapeutics aims to offer FDA-regulated, software-based solutions for conditions like type 2 diabetes and heart disease.
Better Therapeutics (BTTX) announced positive results from its pivotal clinical trial on BT-001, a prescription digital therapeutic for type 2 diabetes. The trial, involving 669 adults, noted a statistically significant A1c reduction of -0.4% (p < 0.001) after 90 days. In financial results for Q4 2021, R&D expenses surged to $6.4 million, while the net loss was $13.9 million, or $0.71 per share. The company reported cash reserves of $40.6 million as of December 31, 2021. Better Therapeutics aims to submit a de novo classification request to the FDA following study completion.
Better Therapeutics, Inc (NASDAQ: BTTX) announced a call on March 25, 2022, to discuss top-line results from its pivotal clinical trial for BT-001, a digital therapeutic aimed at treating type 2 diabetes. The trial showed a clinically significant reduction in A1c levels by -0.4% (p<0.001) without any adverse effects. The company plans to submit a de novo classification request to the FDA following the trial's completion in Q2 2022. The call will focus on the clinical significance of the results and future research expectations.
Better Therapeutics, Inc. (BTTX) announced significant results from the pivotal trial of its investigational digital therapeutic, BT-001, aimed at treating type 2 diabetes. The trial, involving 669 adults, demonstrated a statistically significant reduction in A1c of 0.4% compared to the control group receiving standard care (p <0.001). Key findings included a higher percentage of participants achieving clinically meaningful A1c reductions in the BT-001 group and positive engagement metrics. The company plans to file for FDA approval following trial completion in Q2 2022, highlighting potential Medicare coverage pathways.
Better Therapeutics (NASDAQ: BTTX) has announced an educational symposium titled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.” This event addresses the significant spending on cardiometabolic diseases, emphasizing a shift towards prescription digital therapeutics (PDTs) that utilize cognitive behavioral therapy. The symposium, moderated by a Harvard Medical School cardiologist, focuses on delivering evidence-based solutions to improve patient outcomes and reduce healthcare costs. Better Therapeutics aims to transform treatment approaches with FDA-regulated, software-based solutions.
Better Therapeutics announces significant progress towards reimbursement for its software-based treatment, BT-001, aimed at addressing type 2 diabetes. A new code from the Center for Medicare and Medicaid Services (CMS) will be effective in April 2022, facilitating reimbursement for prescription digital behavioral therapy. CEO Kevin Appelbaum lauds this development as a vital step for adoption. The pivotal study involving 669 patients is set to conclude by Q2 2022, with primary data expected in Q1 2022, followed by an anticipated FDA filing.
Better Therapeutics (NASDAQ: BTTX) has enrolled its first patient in a real-world evidence study to evaluate the long-term effectiveness of BT-001, a prescription digital therapeutic aimed at treating type 2 diabetes. The study is conducted in collaboration with Colorado Prevention Center and seeks to assess healthcare utilization and medication changes. This milestone is part of a multi-year study that may provide insights into glycemic control and healthcare cost reduction, with expectations of delivering robust, real-world data.
Better Therapeutics (NASDAQ: BTTX) announced CEO Kevin Appelbaum will participate in two investor events. The first is a virtual fireside chat on January 26, from 12-1 p.m. EST, discussing treatments for cardiometabolic diseases and the company's lead candidate, BT-001. The second event is the Cowen 42nd Annual Health Care Conference in Boston, MA, on March 7-9, with a chat scheduled on March 7, from 2:10-2:40 p.m. EST. Replays of both sessions will be available on the Better Therapeutics investor site for 90 days.
Better Therapeutics (NASDAQ: BTTX) announced that its pivotal trial for BT-001 in type 2 diabetes is fully enrolled, with primary endpoint data expected in Q1 2022. An early clinical study for nonalcoholic fatty liver disease (NAFLD) is set to start enrollment in the same timeframe. The company has partnered with Mass General Brigham, Colorado Prevention Center, and Catalyst Health Network for a real-world study on BT-001's effectiveness. Recent leadership enhancements are noted, along with coverage initiation by several analysts since its NASDAQ debut.
FAQ
What is the current stock price of BETTER THERAPEUTICS (BTTX)?
What is the market cap of BETTER THERAPEUTICS (BTTX)?
What does Better Therapeutics Inc. do?
How do Better Therapeutics' solutions work?
What makes Better Therapeutics' approach unique?
Can Better Therapeutics' products be used with other treatments?
What recent achievements has Better Therapeutics made?
How does Better Therapeutics impact healthcare costs?
What evidence supports Better Therapeutics' products?
Who can benefit from Better Therapeutics' solutions?
What is the financial condition of Better Therapeutics?
What is the mission of Better Therapeutics?
